SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Shilpa Medicare’s Jadcherla facility

09 Sep 2019 Evaluate

US Food and Drug Administration (USFDA) has concluded inspection at Shilpa Medicare’s Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at S-20 to S-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla in the state of Telangana from August 29, 2019 to September 6, 2019.

The inspection concluded with two observations. There were no repeat observations or Data Integrity (DI) related observations.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

420.20 8.65 (2.10%)
20-Apr-2026 12:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.70
Dr. Reddys Lab 1239.00
Cipla 1239.40
Zydus Lifesciences 942.95
Lupin 2336.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×